Population health consequences of implementation without and with additional research for the HIV self-testing case study
| Implications of decision making without further research | ||
| Expected DALYs averted by programme | 1 884 832 | |
| Expected additional long-term costs associated with programme | US$888 203 454 | |
| Expected health opportunity costs of funding programme (DALYs incurred) | 1 776 407 | |
| Incremental cost-effectiveness ratio (US$/DALY) | US$471 | |
| Expected net DALYs averted by implementation | 108 425 | |
| Implications of decision making informed by further research | Outcomes study | Cost study |
| Value of endpoint at which decision changes* | 0.05† | US$9.98‡ |
| Probability further research could change decision | 0.33 | 0.33 |
| Expected net DALYs averted via research | 41 740 | 89 375 |
| Potential maximum expenditure on study | US$20 870 062 | US$44 687 606 |
| Total expected net DALYs averted | 150 165 | 197 800 |
*The units for this row are the proportion of the targeted population who are diagnosed with HIV in facility-based care for the outcomes study and the cost per person tested in US$ for the cost study.
†This indicates that expanded testing is no longer cost-effective if the proportion of the population who are diagnosed with HIV and linked to care is below 0.05.
‡This indicates that expanded testing is no longer cost-effective if the cost of testing exceeds US$9.98 per individual eligible for testing.
DALY, disability-adjusted life year.